These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31038370)

  • 1. Pharmacotherapy in body dysmorphic disorder: relapse prevention and novel treatments.
    Dong N; Nezgovorova V; Hong K; Hollander E
    Expert Opin Pharmacother; 2019 Jul; 20(10):1211-1219. PubMed ID: 31038370
    [No Abstract]   [Full Text] [Related]  

  • 2. [Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
    Nakamae T
    Seishin Shinkeigaku Zasshi; 2011; 113(10):1016-25. PubMed ID: 22187889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aripiprazole as an augmentation agent in treatment-resistant body dysmorphic disorder.
    Uzun O; Ozdemir B
    Clin Drug Investig; 2010; 30(10):707-10. PubMed ID: 20701402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive antipsychotic in the treatment of body dysmorphic disorder - A retrospective naturalistic case note study.
    Rashid H; Khan AA; Fineberg NA
    Int J Psychiatry Clin Pract; 2015 Jun; 19(2):84-9. PubMed ID: 25363200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
    Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
    Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Body dysmorphic disorder.
    Fang A; Matheny NL; Wilhelm S
    Psychiatr Clin North Am; 2014 Sep; 37(3):287-300. PubMed ID: 25150563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological Treatment of Body Dysmorphic Disorder.
    Hong K; Nezgovorova V; Uzunova G; Schlussel D; Hollander E
    Curr Neuropharmacol; 2019; 17(8):697-702. PubMed ID: 29701157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment-resistant anxiety disorders: A literature review of drug therapy strategies].
    Ammar G; Naja WJ; Pelissolo A
    Encephale; 2015 Jun; 41(3):260-5. PubMed ID: 25439852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in understanding and managing body dysmorphic disorder.
    Krebs G; Fernández de la Cruz L; Mataix-Cols D
    Evid Based Ment Health; 2017 Aug; 20(3):71-75. PubMed ID: 28729345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
    Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
    Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study.
    Phillips KA; Albertini RS; Siniscalchi JM; Khan A; Robinson M
    J Clin Psychiatry; 2001 Sep; 62(9):721-7. PubMed ID: 11681769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy for obsessive-compulsive disorder.
    Dougherty DD; Rauch SL; Jenike MA
    J Clin Psychol; 2004 Nov; 60(11):1195-202. PubMed ID: 15389617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body dysmorphic disorder: diagnostic controversies and treatment challenges.
    Phillips KA
    Bull Menninger Clin; 2000; 64(1):18-35. PubMed ID: 10695157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome in adults with obsessive-compulsive disorder.
    Bloch MH; Green C; Kichuk SA; Dombrowski PA; Wasylink S; Billingslea E; Landeros-Weisenberger A; Kelmendi B; Goodman WK; Leckman JF; Coric V; Pittenger C
    Depress Anxiety; 2013 Aug; 30(8):716-22. PubMed ID: 23532944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of comorbid body dysmorphic disorder on the response to sequential pharmacological trials for obsessive-compulsive disorder.
    Diniz JB; Costa DL; Cassab RC; Pereira CA; Miguel EC; Shavitt RG
    J Psychopharmacol; 2014 Jun; 28(6):603-11. PubMed ID: 24288238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy Relapse Prevention in Body Dysmorphic Disorder: A Double-Blind, Placebo-Controlled Trial.
    Phillips KA; Keshaviah A; Dougherty DD; Stout RL; Menard W; Wilhelm S
    Am J Psychiatry; 2016 Sep; 173(9):887-95. PubMed ID: 27056606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
    Matsunaga H; Nagata T; Hayashida K; Ohya K; Kiriike N; Stein DJ
    J Clin Psychiatry; 2009 Jun; 70(6):863-8. PubMed ID: 19422759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses].
    Sumitani S; Ueno S; Ishimoto Y; Taniguchi T; Tomotake M; Motoki I; Yamauchi K; Ohmori T
    Seishin Shinkeigaku Zasshi; 2006; 108(12):1282-92. PubMed ID: 17334085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder.
    Brakoulias V; Stockings E
    Expert Opin Pharmacother; 2019 Jan; 20(1):47-53. PubMed ID: 30360669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obsessive-Compulsive Disorder: Diagnosis and Management.
    Fenske JN; Petersen K
    Am Fam Physician; 2015 Nov; 92(10):896-903. PubMed ID: 26554283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.